Abstract
Influenza and COVID-19 pandemics are among the deadliest respiratory diseases recorded in the history of humanity. Influenza infections are difficult to diagnose and nearly impossible to predict because the disease symptoms changes as the pathogen(s) evolve. The U.S. was the case study for this research (Latitude: 37.0902°N and Longitude: 95.7129°W). The principle employed in the design of the influenza forecast model was “The Integrated Independent System of Disease Prediction (IISDP)”, where the functionality of one forecast model depends on the predictive capacity of one or more forecast models. It was predicted that 49,734,427 individuals will be infected in 2021 out of the current estimation of 322,900.000 U.S. citizens (only about 1.5% of the total population). The situation was estimated by Etaware-Pred-2021 to worsen in 2050 (300,803,433 infected individuals out of the estimated 400,000,000 U.S. citizens), with a geometric increase in the ratio of infected individuals from 1.5% (in 2021) to 75.2% (in 2050), if necessary health precautions fail. unless there are potent influenza vaccines in circulation, total compliance to influenza vaccination and a high level of personal hygiene among U.S. citizens, influenza infection will become a global threat to humanity. These situations can be averted if the U.S. citizens act accordingly.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The data used for this research are secondary data and as such no registration or permission is required
Funding Statement
No funding was received for this research
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
None required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
the data used for this research are available for review. The data were submitted alongside the manuscript
